Hepatocellular Carcinoma in Adults and Children, An Issue of Clinics in Liver Disease PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Hepatocellular Carcinoma in Adults and Children, An Issue of Clinics in Liver Disease PDF full book. Access full book title Hepatocellular Carcinoma in Adults and Children, An Issue of Clinics in Liver Disease by Adrian Reuben. Download full books in PDF and EPUB format.
Author: Adrian Reuben
Publisher: Elsevier Health Sciences
ISBN: 0323393411
Category : Medical
Languages : en
Pages : 207
Get Book Here
Book Description
Dr. Reuben provides a timely update to the topic of HCC, which was last covered in 2011. The highly respected authors in his issue address advances in imaging for diagnosis, surgical resection and liver transplantation, and local and systemic therapy. The breadth of the topic is covered, with articles devoted to histopathology, classification and staging, and screening and detection.
Author: Adrian Reuben
Publisher: Elsevier Health Sciences
ISBN: 0323393411
Category : Medical
Languages : en
Pages : 207
Get Book Here
Book Description
Dr. Reuben provides a timely update to the topic of HCC, which was last covered in 2011. The highly respected authors in his issue address advances in imaging for diagnosis, surgical resection and liver transplantation, and local and systemic therapy. The breadth of the topic is covered, with articles devoted to histopathology, classification and staging, and screening and detection.
Author: Yujin Hoshida
Publisher: Springer
ISBN: 3030215407
Category : Medical
Languages : en
Pages : 366
Get Book Here
Book Description
This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309153689
Category : Medical
Languages : en
Pages : 252
Get Book Here
Book Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
Author: Philip Rosenthal
Publisher: Elsevier Health Sciences
ISBN: 0323643388
Category : Medical
Languages : en
Pages : 217
Get Book Here
Book Description
With collaboration from Consulting Editor Dr. Norman Gitlin, Dr. Rosenthal has created an issue that provides current clinical information on the diagnosis and treatment of liver diseases in children. Expert authors from top institutions have contributed review articles on the following topics: Biliary atresia; Alagille Syndrome; Hepatitis B & C in Children; NAFLD/NASH; Bile acid defects; Progressive Familial Intrahepatic Cholestasis; Autoimmune hepatitis/PSC/Overlap syndrome; Portal hypertension/Cirrhosis in Children; Alpha-1-antitrypsin deficiency; Hepatic tumors; Acute Liver Failure; and Liver transplantation in Children. Readers will come away with the information they need to make clinical decisions that will improve patient outcomes.
Author: Edward L. Krawitt
Publisher: Elsevier Science Health Science Division
ISBN: 9780444828033
Category : Medical
Languages : en
Pages : 656
Get Book Here
Book Description
The second edition, which appears seven years after the first, is a more comprehensive text and addresses the many recent advances in basic and clinical science applicable to autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune aspects of viral-, drug- and alcohol-induced liver disease and hepatocellular cancer. Pathogenesis, diagnosis and treatment are discussed in depth in light of current understanding of the molecular mechanisms of autoimmunity as it applies to liver disease.
Author: Philip Rosenthal
Publisher: Elsevier Health Sciences
ISBN: 032389755X
Category : Medical
Languages : en
Pages : 233
Get Book Here
Book Description
In this issue, guest editors bring their considerable expertise to this important topic.Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
Author: Paul J. Gaglio
Publisher: Elsevier Health Sciences
ISBN: 0323416977
Category : Medical
Languages : en
Pages : 195
Get Book Here
Book Description
Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.
Author: Cynthia Levy
Publisher: Elsevier Health Sciences
ISBN: 0323429920
Category : Medical
Languages : en
Pages : 225
Get Book Here
Book Description
Dr. Levy has secured the field’s top experts to offer the latest clinical reviews on cholestatic liver disease. The issue will include articles devoted to The Gut-Liver Axis; Update on Genetics in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis; New thoughts on IgG4 Associated Cholangitis; Cancer Risk and Surveillance in PSC; Novel Therapies for PBC; and Liver transplantation for Cholestatic Liver Diseases, to name a few. Dr. Levy’s issue will be the most current authority on cholestatic liver disease.
Author: Tarek I. Hassanein
Publisher: Elsevier Health Sciences
ISBN: 0323477054
Category : Medical
Languages : en
Pages : 161
Get Book Here
Book Description
HBV is most prevalent viral infection worldwide. Recent advances in HBV virology epidemiology and management are of utmost importance particularly during this time when HCV is taking the front row in discussion and research. However, there’s an increased interest in management of HBV in special populations, which is covered in this issue. The authors also explore drugs in the pipeline as well as new approaches for achieving long-term viral suppression and possibly cure.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187
Get Book Here
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
